{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:13:10Z","timestamp":1793833990207,"version":"4.6.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.semarthrit.2020.04.010","type":"journal-article","created":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T14:32:36Z","timestamp":1593527556000},"page":"S24-S30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"special_numbering":"S","title":["Therapeutic approaches in the treatment of gout"],"prefix":"10.1016","volume":"50","author":[{"given":"Michael H.","family":"Pillinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Mandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.semarthrit.2020.04.010_bib0001","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.04.010_bib0002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11926-017-0688-y","article-title":"Gout and metabolic syndrome: a tangled web","volume":"19","author":"Thottam","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.04.010_bib0003","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.39254","article-title":"2015 Gout Classification Criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"67","author":"Neogi","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0004","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","article-title":"Inflammation in gout: mechanisms and therapeutic targets","volume":"13","author":"So","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"7081","key":"10.1016\/j.semarthrit.2020.04.010_bib0005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.04.010_bib0006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/icb.2009.98","article-title":"Crystal-induced neutrophil activation","volume":"88","author":"Popa-Nita","year":"2010","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.04.010_bib0007","first-page":"189","article-title":"The year in gout: 2012-2013 \u2013 a walk through the 2012 ACR Gout Treatment Guidelines","volume":"71","author":"Crittenden","year":"2013","journal-title":"Bull Hosp Jt Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.04.010_bib0008","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0009","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/kel071","article-title":"Effectiveness of interventions for the treatment of acute and prevention of recurrent gout \u2013 a systematic review","volume":"45","author":"Sutaria","year":"2006","journal-title":"Rheumatology"},{"issue":"Suppl 9","key":"10.1016\/j.semarthrit.2020.04.010_bib0010","first-page":"S93","article-title":"A study of the platelet effects of SC-58635, a novel COX-2 selective inhibitor","volume":"40","author":"Mentle-Gaw","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.04.010_bib0011","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/j.1552-4604.1991.tb03743.x","article-title":"Nonsteroidal anti-inflammatory drugs: effects on kidney function","volume":"31","author":"Whelton","year":"1991","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.04.010_bib0012","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3899\/jrheum.110916","article-title":"Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial","volume":"39","author":"Schumacher","year":"2012","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.04.010_bib0013","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.04.010_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.prostaglandins.2018.10.005","article-title":"Variability in analgesic response to non-steroidal anti-inflammatory drugs","volume":"139","author":"Theken","year":"2018","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.04.010_bib0016","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/M14-2070","article-title":"Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial","volume":"164","author":"Rainer","year":"2016","journal-title":"Ann Intern Med"},{"issue":"suppl1","key":"10.1016\/j.semarthrit.2020.04.010_bib0017","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","article-title":"Update on colchicine, 2017","volume":"57","author":"Slobodnick","year":"2018","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.04.010_bib0018","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","article-title":"The role of interleukin-1 and the inflammasome in gout: implications for therapy","volume":"56","author":"Pope","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.04.010_bib0019","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.04.010_bib0020","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/p-glycoprotein inhibitors","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.04.010_bib0021","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: the dark side of an ancient drug","volume":"48","author":"Finkelstein","year":"2010","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0022","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev-med-080911-105830","article-title":"New therapies for gout","volume":"64","author":"Crittenden","year":"2013","journal-title":"Annu Rev Med"},{"issue":"suppl 10","key":"10.1016\/j.semarthrit.2020.04.010_bib0023","article-title":"A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study [abstract]","volume":"71","author":"Saag","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.04.010_bib0024","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","article-title":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomized, multicenter, active-controlled, double-blind trials and their initial extensions","volume":"71","author":"Schlesinger","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.04.010_bib0025","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/acr.21690","article-title":"Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study","volume":"64","author":"Jr","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.04.010_bib0026","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/rheumatology\/ket114","article-title":"Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial","volume":"52","author":"Mitha","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key402","article-title":"Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial","author":"Janssen","year":"2019","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.04.010_bib0028","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.04.010_bib0029","first-page":"324","article-title":"Essence of the revised guideline for the management of hyperuricemia and gout","volume":"55","author":"Yamanaka","year":"2012","journal-title":"Japan Med Assoc J"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.04.010_bib0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/M16-0570","article-title":"Clinical Guidelines Committee of the American College of Physicians. Management of acute and recurrent gout: a clinical practice guideline from the American College of Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.04.010_bib0031","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrrheum.2017.126","article-title":"Discordant America College of Physicians and international rheumatology guidelines for gout management: consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)","volume":"13","author":"Dalbeth","year":"2017","journal-title":"Nat Rev Rheumtol"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.04.010_bib0032","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/art.30649","article-title":"A two-stage approach to the treatment of hyperuricemia in gout: the \u201cdirty dish\u201d hypothesis","volume":"63","author":"Perez-Ruiz","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.04.010_bib0033","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40265-019-01081-5","article-title":"Cardiovascular disease in gout and the protective effect of treatments including urate-lowering therapy","volume":"79","author":"Gupta","year":"2019","journal-title":"Drugs"},{"issue":"suppl1","key":"10.1016\/j.semarthrit.2020.04.010_bib0034","doi-asserted-by":"crossref","first-page":"i47","DOI":"10.1093\/rheumatology\/kex432","article-title":"Cardiac and renal protective effects of urate-lowering therapy","volume":"57","author":"Richette","year":"2018","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.04.010_bib0035","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.semarthrit.2018.06.004","article-title":"Combination urate-lowering therapy in the treatment of gout: What is the evidence","volume":"48","author":"Perez-Ruiz","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0036","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2350-12-118","article-title":"Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis","volume":"12","author":"Somkrua","year":"2011","journal-title":"BMC Med Genet"},{"issue":"suppl1","key":"10.1016\/j.semarthrit.2020.04.010_bib0037","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/rheumatology\/kex422","article-title":"How to prevent allopurinol hypersensitivity reactions","volume":"57","author":"Stamp","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0038","unstructured":"Dean L. Medical Genetics Summaries: National Center for Biotechnology Information (US):2012-2013."},{"issue":"23","key":"10.1016\/j.semarthrit.2020.04.010_bib0039","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cct.2018.03.015","article-title":"Design and rationale for the Veterans Affairs \u201cCooperative Study Program 594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat\u201d trial","volume":"68","author":"Timilsina","year":"2018","journal-title":"Contemp Clin Trials"},{"issue":"13","key":"10.1016\/j.semarthrit.2020.04.010_bib0041","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0042","unstructured":"US Food and Drug Administration. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). 2019. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat; Accessed 5 August 2019."},{"issue":"11","key":"10.1016\/j.semarthrit.2020.04.010_bib0043","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/art.40583","article-title":"New perspectives in rheumatology: Implications of the cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular morbidities trial and the associated Food and Drug Administration public safety alert","volume":"70","author":"Choi","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0044","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez189","article-title":"Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nationwide cohort study","author":"Kang","year":"2019","journal-title":"Rheumatology"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.04.010_bib0045","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in order patients with gout initiating febuxostat versus allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0046","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005354","article-title":"Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomized, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia","volume":"4","author":"MacDonald","year":"2014","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.04.010_bib0047","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1152\/ajpcell.00227.2008","article-title":"Probenecid, a gout remedy, inhibits pannexin 1 channels","volume":"295","author":"Silverman","year":"2008","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.04.010_bib0048","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MAJ.0b013e31815acb10","article-title":"Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy","volume":"335","author":"Chung","year":"2008","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.04.010_bib0049","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40266-017-0461-y","article-title":"Lesinurad: A review in hyperuricaemia of gout","volume":"34","author":"Deeks","year":"2017","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.04.010_bib0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/rheumatology\/key245","article-title":"Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout","volume":"58","author":"Terkeltaub","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0051","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212581","article-title":"Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout","volume":"8","author":"Perez-Ruiz","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0052","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J Mol Evol"},{"issue":"7-8","key":"10.1016\/j.semarthrit.2020.04.010_bib0053","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1345\/aph.1C336","article-title":"Rasburicase for the treatment and prevention of hyperuricemia","volume":"37","author":"Yim","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.04.010_bib0054","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13075-018-1782-x","article-title":"Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase","volume":"20","author":"Mandell","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0055","article-title":"Dissociation between clinical benefit and persistent urate lowering in patients with chronic refractory gout treated with pegloticase","author":"Pillinger","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0056","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis ResTher"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0057","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.semarthrit.2016.09.007","article-title":"Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout","volume":"46","author":"Berhanu","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"14","key":"10.1016\/j.semarthrit.2020.04.010_bib0058","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials","volume":"32","author":"Wortmann","year":"2010","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.04.010_bib0059","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2017-211574","article-title":"Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicenter randomized study","volume":"77","author":"Yamanaka","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0060","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","article-title":"Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomized controlled trial","volume":"392","author":"Doherty","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0061","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, daily and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.04.010_bib0062","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/art.20821","article-title":"liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey","volume":"51","author":"Choi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0063","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0026-0495(75)90133-X","article-title":"Stimulation of human purine synthesis de novo by fructose infusion","volume":"24","author":"Raivio","year":"1975","journal-title":"Metabolism"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0064","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/art.39107","article-title":"A role for gut microbiota and the metabolite-sensing receptor GPR43 in a murine model of gout","volume":"67","author":"Vieira","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.04.010_bib0065","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3949\/ccjm.81a.13131","article-title":"Should patients with gout avoid thiazides for hypertension?","volume":"81","author":"Mandell","year":"2014","journal-title":"Cleve Clin J Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.04.010_bib0066","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13075-018-1559-2","article-title":"Impact of diuretics on the urate lowering therapy in patients with gout: analysis of an inception cohort","volume":"20","author":"Ranieri","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.04.010_bib0067","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese Society of Gout and Nucleic Acid Metabolism. Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"39","author":"Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.04.010_bib0068","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis & Rheumatology"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220301244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220301244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:02:54Z","timestamp":1758733374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220301244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0049017220301244"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approaches in the treatment of gout","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}